An interventional study of Oxygen therapy - constant oxygen flow and Oxygen therapy - automatic titrating oxygen flow in Hypoxaemia and Chronic Lung Disease, sponsored by Schön Klinik Berchtesgadener Land. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-08-13.
Sponsored by Schön Klinik Berchtesgadener Land · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Hypoxia with a site in Germany — 4 open to participants now, 4 under way, 1 of them phase 3. Hypoxia · Germany.
Among the 35 studies in Hypoxia with a site in Germany, this one is the 28th largest by planned enrollment of the 30 interventional ones that give a count, is the only one that started in 2023, is one of 22 with no phase, and was the 35th registered.
1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.
Browse Hypoxia studies →4 of the 35 studies in Hypoxia with a site in Germany are open now. Recruiting first, the newest first:
Australian and New Zealand Intensive Care Research Centre · Sites in Germany, Australia
Ages 18–65
University of Giessen · Sites in Germany
Ages 18+
Technical University of Munich · Sites in Germany
Ages 18–70
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 6
First in 2003; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 15 is below the median of 45 across 771 interventional studies indexed under Hypoxia.
Median enrollment 35 across the 30 interventional studies, 140 across the 4 observational. Of the 27 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 35 has an industry lead sponsor. The 10 most frequent:
Schön Klinik Berchtesgadener Land is the lead sponsor of 51 studies on the registry; 2 are open to participants now.
Schön Klinik Berchtesgadener Land has 3 studies filed under Hypoxia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Hypoxia with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Long-term oxygen therapy is a fundamental treatment modality for patients with chronic hypoxaemic lung disease. Typically, oxygen is administered at a constant flow rate. However, due to fluctuating activity levels, patients' oxygenation status can vary, potentially leading to oxygen desaturation and increased dyspnoea.
Emerging evidence suggests that automatic oxygen titration - a method of adjusting oxygen flow in response to current oxygen saturation - may have acute advantages over constant oxygen flow.
The primary objective of this study is to investigate the effect of automatic oxygen titration compared to prescribed constant oxygen flow rates on patients' perceived dyspnoea during exercise endurance training.
Rationale:
Hypoxaemia is common in people with chronic lung disease and can affect exercise tolerance. Oxygen therapy is then recommended.
Oxygen supplementation is usually delivered at constant oxygen flow rates. Only a few studies have investigated the short-term effects of automated oxygen delivery compared to a constant oxygen flow rate during exercise tests (e.g. 6-minute walk test, shuttle walk tests). These studies have shown that automatic oxygen delivery can lead to an acute increase in exercise capacity, including an improvement in the perception of breathlessness. The use of automated oxygen delivery during endurance exercise has not been studied. The most common reason for stopping prolonged exercise in patients with chronic lung disease is dyspnoea. Therefore, the use of automatic oxygen delivery in a pulmonary rehabilitation clinic could be beneficial in the context of personalised therapy for patients requiring oxygen if it further reduces dyspnoea, potentially enabling the patient to train their endurance even better.
Therefore, the primary aim of this study was to investigate whether the use of automatic oxygen supplementation versus constant oxygen supplementation has a different effect on the perception of dyspnoea in patients with hypoxaemia during endurance exercise.
Design:
This study is designed as a randomised, double-blind, controlled cross-over trial. Participants will first undergo a cycle-based peak work rate test to determine their individual maximal peak work rate. They then take part in two sets of five endurance training sessions. One set is performed with a constant oxygen flow prescribed for each participant, while the other uses automatic oxygen titration. The order in which these two sessions are performed is randomised.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The first series of five exercise trainings (A) involves supplemental oxygen therapy, with automatically titrated oxygen flow rates to maintain an oxygen saturation of 90-94% (A). The second series of five exercise trainings employs supplemental oxygen therapy with constant flow rates (B), as prescribed.
Other: Oxygen therapy - constant oxygen flow · Other: Oxygen therapy - automatic titrating oxygen flow
The first series of five exercise trainings employs supplemental oxygen therapy with constant flow rates (B), as prescribed.The second five series of five exercise trainings involves supplemental oxygen therapy, with automatically titrated oxygen flow rates to maintain an oxygen saturation of 90-94% (A).
Other: Oxygen therapy - constant oxygen flow · Other: Oxygen therapy - automatic titrating oxygen flow
During five exercise training sessions, oxygen therapy is delivered via prescribed constant oxygen flow
During five exercise sessions, oxygen therapy is delivered via an automatically titrated oxygen flow rate to maintain an SpO2 target of 90-94%.
Dyspnea
Change of dyspnea sensation rated by modified Borg scale (0 to 10) taken before and after exercise training
Time frame: Day 1 to 5 and 6 to 10
Change of oxygen saturation (SpO2) during exercise training
SpO2 measured by continuous transcutaneous recordung via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland).
Time frame: Day 1 to 5 and 6 to 10
Change of transcutaneous partial CO2 pressure (TcPCO2) during exercise training
TcPCO2 measured by continuous transcutaneous recording via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland)
Time frame: Day 1 to 5 and 6 to 10
Change of heart rate during exercise training
Heart rate measured by continuous transcutaneous recordung via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland).
Time frame: Day 1 to 5 and 6 to 10
Change of capillary partial pressure of CO2 (pCO2) during exercise training
pCO2 measured by capillary blood gases taken before and after the exercise training
Time frame: Day 1 to 5 and 6 to 10
Change of capillary partial pressure of O2 (pO2) during exercise training
pO2 measured by capillary blood gases taken before and after the exercise training
Time frame: Day 1 to 5 and 6 to 10
Change of inspiratory capacity (IC) during exercise training
IC measured by Spirometry taken before and after exercise training via SpiroSense Pro® (Pari, Starnberg, Germany)
Time frame: Day 1 to 5 and 6 to 10
Time to desaturation (SpO2 <=90%) and to severe desaturation (SpO2 <=85%) during exercise training
SpO2 measured by continuous transcutaneous recordung via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland)
Time frame: Day 1 to 5 and 6 to 10
Assessment of leg fatigue via BORG scale
Change of leg fatigue assessed by modified Borg scale (0 to 10) taken before and after exercise training
Time frame: Day 1 to 5 and 6 to 10
Patients sensation regarding the oxygen delivery system
Patients will be asked to rate their experienced comfort after Session 1 and Session 2 via a 5-point Likert Skale: strongly agree, agree, neutral, disagree, strongly disagree
Time frame: Day 5 and 10
Started Aug 2023 (actual). Primary completion is estimated for Nov 2024, 15 months after the start.
Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 15 months is above that.
Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Schön Klinik Berchtesgadener Land